US 12,678,408

Application 19/545,594 · Granted Jul 14, 2026

Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine

Estimated expiration

June 29, 2036

9y 223d remaining

Confidence: medium
Medium: a terminal disclaimer was found but the patents it references could not be read, or several warnings were raised. Read the notes under the details.
  • Could not fetch continuity data for application 17984290: Resource not found (404)
  • Could not fetch continuity data for application 17667674: Resource not found (404)
  • Could not fetch continuity data for application 17386089: Resource not found (404)
  • Could not fetch continuity data for application 17148765: Resource not found (404)
  • Could not fetch continuity data for application 16923139: Resource not found (404)
  • Could not fetch continuity data for application 16690272: Resource not found (404)
  • Application 19048549 has not been granted a patent number
  • Application 19451185 has not been granted a patent number
Earliest effective filing
Jun 29, 2016
+ 20 years
Jun 29, 2036
PTA +0d
Jun 29, 2036
TD applied
Jun 29, 2036
Final
Jun 29, 2036

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
February 20, 2026
Earliest effective filing
June 29, 2016
Issue date
July 14, 2026
PTA
0 days
Base expiry (before PTA)
June 29, 2036

June 29, 2016 + 20 years = June 29, 2036

  • Continuation of application 19/048,549, filed Feb 7, 2025
  • Continuation of application 18/782,290, filed Jul 24, 2024
  • Continuation of application 18/539,583, filed Dec 14, 2023
  • Continuation of application 18/204,012, filed May 31, 2023
  • Continuation of application 17/984,290, filed Nov 10, 2022
  • Continuation of application 17/667,674, filed Feb 9, 2022
  • Continuation of application 17/386,089, filed Jul 27, 2021
  • Continuation of application 17/148,765, filed Jan 14, 2021
  • Continuation of application 16/923,139, filed Jul 8, 2020
  • Continuation of application 16/690,272, filed Nov 21, 2019
  • Continuation of application 15/197,491, filed Jun 29, 2016
  • Continuation of application 17/984,290, filed Nov 10, 2022
  • Continuation of application 17/667,674, filed Feb 9, 2022
  • Continuation of application 17/386,089, filed Jul 27, 2021
  • Continuation of application 17/148,765, filed Jan 14, 2021
  • Continuation of application 16/923,139, filed Jul 8, 2020
  • Continuation of application 16/690,272, filed Nov 21, 2019
  • Continuation of application 15/197,491, filed Jun 29, 2016
  • Continuation of application 18/204,012, filed May 31, 2023
  • Continuation of application 17/984,290, filed Nov 10, 2022
  • Continuation of application 17/667,674, filed Feb 9, 2022
  • Continuation of application 17/386,089, filed Jul 27, 2021
  • Continuation of application 17/148,765, filed Jan 14, 2021
  • Continuation of application 16/923,139, filed Jul 8, 2020
  • Continuation of application 16/690,272, filed Nov 21, 2019
  • Continuation of application 15/197,491, filed Jun 29, 2016
  • Continuation of application 18/539,583, filed Dec 14, 2023
  • Continuation of application 18/204,012, filed May 31, 2023
  • Continuation of application 17/984,290, filed Nov 10, 2022
  • Continuation of application 17/667,674, filed Feb 9, 2022
  • Continuation of application 17/386,089, filed Jul 27, 2021
  • Continuation of application 17/148,765, filed Jan 14, 2021
  • Continuation of application 16/923,139, filed Jul 8, 2020
  • Continuation of application 16/690,272, filed Nov 21, 2019
  • Continuation of application 15/197,491, filed Jun 29, 2016
  • Continuation of application 18/782,290, filed Jul 24, 2024
  • Continuation of application 18/539,583, filed Dec 14, 2023
  • Continuation of application 18/204,012, filed May 31, 2023
  • Continuation of application 17/984,290, filed Nov 10, 2022
  • Continuation of application 17/667,674, filed Feb 9, 2022
  • Continuation of application 17/386,089, filed Jul 27, 2021
  • Continuation of application 17/148,765, filed Jan 14, 2021
  • Continuation of application 16/923,139, filed Jul 8, 2020
  • Continuation of application 16/690,272, filed Nov 21, 2019
  • Continuation of application 15/197,491, filed Jun 29, 2016
  • PRO62/317,286 — Provisional — not used for base term
  • PRO62/301,429 — Provisional — not used for base term
  • PRO62/298,373 — Provisional — not used for base term
  • PRO62/187,113 — Provisional — not used for base term
  • PRO62/317,286 — Provisional — not used for base term
  • PRO62/301,429 — Provisional — not used for base term
  • PRO62/298,373 — Provisional — not used for base term
  • PRO62/187,113 — Provisional — not used for base term
  • PRO62/317,286 — Provisional — not used for base term
  • PRO62/301,429 — Provisional — not used for base term
  • PRO62/298,373 — Provisional — not used for base term
  • PRO62/187,113 — Provisional — not used for base term
  • PRO62/317,286 — Provisional — not used for base term
  • PRO62/301,429 — Provisional — not used for base term
  • PRO62/298,373 — Provisional — not used for base term
  • PRO62/187,113 — Provisional — not used for base term
  • PRO62/317,286 — Provisional — not used for base term
  • PRO62/301,429 — Provisional — not used for base term
  • PRO62/298,373 — Provisional — not used for base term
  • PRO62/187,113 — Provisional — not used for base term
  • PRO62/317,286 — Provisional — not used for base term
  • PRO62/301,429 — Provisional — not used for base term
  • PRO62/298,373 — Provisional — not used for base term
  • PRO62/187,113 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to June 29, 2036

  • US 12,678,408· Application 19/545,594(from application 19/545,594)Capping patent

    Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine

    Filing date
    Feb 20, 2026
    Earliest effective filing
    Jun 29, 2016
    Issue date
    Jul 14, 2026
    PTA
    0 days
    Calculated expiration
    Jun 29, 2036

    Continuation of 19/048,549, filed Feb 7, 2025

    Continuation of 18/782,290, filed Jul 24, 2024

    Continuation of 18/539,583, filed Dec 14, 2023

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 18/539,583, filed Dec 14, 2023

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 18/782,290, filed Jul 24, 2024

    Continuation of 18/539,583, filed Dec 14, 2023

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Jun 29, 2016 + 20y = Jun 29, 2036

  • US APP:19048549(from application 19/048,549)

    Could not resolve calculation details

  • US 12,629,338· Application 19/451,093(from application 19/451,093)

    Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine

    Filing date
    Jan 16, 2026
    Earliest effective filing
    Jun 29, 2016
    Issue date
    May 19, 2026
    PTA
    0 days
    Calculated expiration
    Jun 29, 2036

    Continuation of 19/048,549, filed Feb 7, 2025

    Continuation of 18/782,290, filed Jul 24, 2024

    Continuation of 18/539,583, filed Dec 14, 2023

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 18/539,583, filed Dec 14, 2023

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 18/782,290, filed Jul 24, 2024

    Continuation of 18/539,583, filed Dec 14, 2023

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Jun 29, 2016 + 20y = Jun 29, 2036

  • US APP:19451185(from application 19/451,185)

    Could not resolve calculation details

  • US 12,661,323· Application 19/461,014(from application 19/461,014)

    Pharmaceutical formulations comprising tenofovir alafenamide and emtricitabine

    Filing date
    Jan 27, 2026
    Earliest effective filing
    Jun 29, 2016
    Issue date
    Jun 23, 2026
    PTA
    0 days
    Calculated expiration
    Jun 29, 2036

    Continuation of 19/048,549, filed Feb 7, 2025

    Continuation of 18/782,290, filed Jul 24, 2024

    Continuation of 18/539,583, filed Dec 14, 2023

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 18/539,583, filed Dec 14, 2023

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Continuation of 18/782,290, filed Jul 24, 2024

    Continuation of 18/539,583, filed Dec 14, 2023

    Continuation of 18/204,012, filed May 31, 2023

    Continuation of 17/984,290, filed Nov 10, 2022

    Continuation of 17/667,674, filed Feb 9, 2022

    Continuation of 17/386,089, filed Jul 27, 2021

    Continuation of 17/148,765, filed Jan 14, 2021

    Continuation of 16/923,139, filed Jul 8, 2020

    Continuation of 16/690,272, filed Nov 21, 2019

    Continuation of 15/197,491, filed Jun 29, 2016

    Jun 29, 2016 + 20y = Jun 29, 2036

Notes (1)

  • [TD_REFS_TRUNCATED] Found 6 TD references; resolving first 5 only

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 19/545,594 · US 12,678,408

PatentReply compiles the prosecution history behind US 12,678,408: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12678408

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.